QMPSB

QMPSB
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act;
Identifiers
	IUPAC name 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate;
CAS Number	312606-87-4;
PubChem CID	3929482;
ChemSpider	3151524;
UNII	55Q8B94HS5;
ChEMBL	ChEMBL245876;
CompTox Dashboard (EPA)	DTXSID901045939 ;
Chemical and physical data
Formula	C22H22N2O4S
Molar mass	410.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1ccc(cc1[S](=O)(=O)N2CCCCC2)C(=O)Oc3cccc4cccnc34;
	InChI InChI=1S/C22H22N2O4S/c1-16-10-11-18(15-20(16)29(26,27)24-13-3-2-4-14-24)22(25)28-19-9-5-7-17-8-6-12-23-21(17)19/h5-12,15H,2-4,13-14H2,1H3; Key:WORIMYADZQJWOU-UHFFFAOYSA-N;

QMPSB is an arylsulfonamide-based synthetic cannabinoid that has been sold as a designer drug.^[1]

Quick Facts Legal status, Identifiers ...

QMPSB was first discovered by Nathalie Lambeng and colleagues in 2007. It acts as a full agonist of the CB₁ receptor and CB₂ receptor with K_i values of 3 nM and 4 nM, respectively.^[2] Many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive CB₂ receptor.^[3]^[4]^[5]^[6] This work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004.^[7]

The quinolin-8-yl ester motif of QMPSB led to the discovery of other designer cannabinoids such as PB-22 and BB-22.^[8]

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

QMPSB

See also

References

Wikiwand - on